Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Sunday's Exclusive Article A Fresh IPO That Long-Term Investors Shouldn't IgnoreBy Jordan Chussler. Date Posted: 1/14/2026. 
Key Takeaways - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Almost every week, companies go public, and a handful offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. Still, even conservative investors shouldn't overlook some recently public companies, as a few may deserve a place in buy-and-hold portfolios. History doesn't repeat perfectly, but it often rhymes.
Several economic indicators today — elevated market valuations, record margin debt, and widening wealth inequality — are being compared by economists to conditions that existed before past major downturns. At the same time, algorithmic trading and rapid capital flows mean market stress can accelerate faster than in previous decades.
In response, some investors are revisiting diversification strategies that include tangible assets, such as physical gold, as part of long-term wealth preservation planning.
A free educational guide explores these historical parallels and explains IRS-approved ways Americans can hold physical gold inside retirement accounts as a diversification tool. Download the free 2026 Wealth Preservation Guide here One biotechnology company in the healthcare sector that just went public could be such a candidate. Last Year's IPO Success Stories Last year provides a strong example of why newly public companies shouldn't be dismissed by investors with lower risk tolerances. AI cloud computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since then. Short-term speculators may have capitalized on its nearly 359% gain before it reached 30 days on the Nasdaq, but those who held on are still enjoying strong returns. Others, such as Medline (NASDAQ: MDLN), refute the idea that IPOs are only risky startups. The medical products and services provider, which debuted in December 2025, was founded in 1966 and already has a market cap in excess of $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD)—known for its ubiquitous packages of bacon—waited 89 years before its IPO. Since going public in January 2025, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44% (about $1 per share annually), making it an immediate consideration for income investors. After its IPO and with shares hitting the market on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a maker of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals—a subset of nuclear medicine that uses radioactive drugs for both diagnostics and treatment of conditions including cancer, heart disease and neurological disorders. Radiopharmaceuticals combine radioactive isotopes with targeting molecules that seek out particular cells (for example, cancer cells) to deliver localized radiation doses, minimizing harm to healthy tissue compared with less targeted treatments. According to industry consultancy Grand View Research, the global nuclear medicine market—estimated at nearly $18 billion in 2024—is forecast to reach nearly $35 billion by 2030, a compound annual growth rate of about 10.16%. For Boston-based Aktis Oncology, Grand View Research notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant player. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPOs to rebound in 2026 after policy-driven funding shifts slowed healthcare listings in 2025. Aktis Oncology, which debuted on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised one of the largest sums for a biotech listing in recent memory. With $318 million raised in the IPO, the firm now has a market cap of about $3.34 billion. According to the company's prospectus, the executive team includes experienced drug developers and commercial leaders, with members of management having participated in bringing 14 currently FDA-approved products to market. At a technical level, Aktis develops targeted alpha radiopharmaceuticals, a class of precision cancer drugs that use proprietary technology to target solid tumors while sparing healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting a major strategic partner: Eli Lilly (NYSE: LLY), which anchored its IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares as part of the offering. That investment builds on a 2024 collaboration between the two companies to develop tumor-targeting radiopharmaceuticals. Under that agreement, Aktis received $60 million in cash along with an equity investment by Eli Lilly, and the partnership includes potential milestone payments in excess of $1 billion. The significance of Eli Lilly's backing cannot be overstated. With a market cap around $1.01 trillion, Eli Lilly is one of the largest pharmaceutical companies by market value after net income (profit) jumped nearly 109% year-over-year from 2023 to 2024. That momentum is likely to be in focus when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the recent $100 million purchase of AKTS shares, the maker of Zepbound now has a sizable financial interest in the biotech startup's success.
| 
